Lexicon Pharmaceuticals, Inc., The Woodlands, TX 77381, USA.
MKTXS, Raritan, NJ 08869, USA.
Future Oncol. 2019 Apr;15(12):1397-1406. doi: 10.2217/fon-2018-0960. Epub 2019 Feb 8.
Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9-17.0%; = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA. Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.
神经内分泌肿瘤 (NETs) 患者中升高的血清素可能会影响心力衰竭的发病率，但尚未建立定量关系。系统评价和荟萃分析了评估 NETs 患者 24 小时尿 5-羟吲哚乙酸 (u5-HIAA) 和死亡率的研究（2007-2017 年），主要结局为 1 年死亡率风险和 24 小时 u5-HIAA。我们确定了 1715 条记录，其中 12 项研究包括 755 名患者（3442 人年，376 例死亡）符合荟萃分析的条件。平均 u5-HIAA 为 149.2mg/24 h（标准差：96.6），死亡率为 13.0%。荟萃回归方程显示，u5-HIAA 每增加 10 个单位，1 年死亡率就会增加 11.8%（95%CI：8.9-17.0%；P<0.001）。其代谢物 u5-HIAA 测定的血清素可预测 NETs 患者的 1 年全因死亡率。
